Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Nov;41(11):2367–2373. doi: 10.1128/aac.41.11.2367

In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates.

K T Chong 1, P J Pagano 1
PMCID: PMC164130  PMID: 9371335

Abstract

PNU-140690 (sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrone) is a potent, nonpeptidic inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease currently under clinical evaluation. PNU-140690 and ritonavir were studied in two-drug combinations against the replication of HIV-1 clinical isolates in peripheral blood mononuclear cells. A ritonavir-sensitive (301-1x) and -resistant (301-6x) isolate pair derived from an individual before and after monotherapy with ritonavir were used. These isolates showed no significant difference in sensitivity to PNU-140690, but isolate 301-6x was more than 50-fold less sensitive to ritonavir than isolate 301-1x. Mathematical analysis showed that the combination of various concentrations of PNU-140690 with ritonavir yielded additive to moderately synergistic antiviral effects against the ritonavir-sensitive isolate and stronger synergy against the ritonavir-resistant isolate. The mechanism of synergy was not investigated, but the results suggested that both the virological and the observed in vitro pharmacological effects may have contributed to the observed synergy. Importantly, no significant antagonism was observed with the drug combinations studied. These data suggest that PNU-140690 may be useful in combination regimens with a structurally unrelated protease inhibitor such as ritonavir.

Full Text

The Full Text of this article is available as a PDF (249.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belen'kii M. S., Schinazi R. F. Multiple drug effect analysis with confidence interval. Antiviral Res. 1994 Sep;25(1):1–11. doi: 10.1016/0166-3542(94)90089-2. [DOI] [PubMed] [Google Scholar]
  2. Bianchi V., Borella S., Calderazzo F., Ferraro P., Chieco Bianchi L., Reichard P. Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8403–8407. doi: 10.1073/pnas.91.18.8403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boucher C. Rational approaches to resistance: using saquinavir. AIDS. 1996 Nov;10 (Suppl 1):S15–S19. [PubMed] [Google Scholar]
  4. Chong K. T., Pagano P. J., Hinshaw R. R. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother. 1994 Feb;38(2):288–293. doi: 10.1128/aac.38.2.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chong K. T., Pagano P. J. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. Antiviral Res. 1997 Mar;34(1):51–63. doi: 10.1016/s0166-3542(96)01021-2. [DOI] [PubMed] [Google Scholar]
  6. Chou T. C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4. [DOI] [PubMed] [Google Scholar]
  7. Coffin J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483–489. doi: 10.1126/science.7824947. [DOI] [PubMed] [Google Scholar]
  8. Collier A. C., Coombs R. W., Schoenfeld D. A., Bassett R. L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V. J. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996 Apr 18;334(16):1011–1017. doi: 10.1056/NEJM199604183341602. [DOI] [PubMed] [Google Scholar]
  9. Collier A. C., Coombs R. W., Schoenfeld D. A., Bassett R., Baruch A., Corey L. Combination therapy with zidovudine, didanosine and saquinavir. Antiviral Res. 1996 Jan;29(1):99–99. doi: 10.1016/0166-3542(95)00928-0. [DOI] [PubMed] [Google Scholar]
  10. Condra J. H., Holder D. J., Schleif W. A., Blahy O. M., Danovich R. M., Gabryelski L. J., Graham D. J., Laird D., Quintero J. C., Rhodes A. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996 Dec;70(12):8270–8276. doi: 10.1128/jvi.70.12.8270-8276.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Condra J. H., Schleif W. A., Blahy O. M., Gabryelski L. J., Graham D. J., Quintero J. C., Rhodes A., Robbins H. L., Roth E., Shivaprakash M. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995 Apr 6;374(6522):569–571. doi: 10.1038/374569a0. [DOI] [PubMed] [Google Scholar]
  12. Danner S. A., Carr A., Leonard J. M., Lehman L. M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., Pintado V. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995 Dec 7;333(23):1528–1533. doi: 10.1056/NEJM199512073332303. [DOI] [PubMed] [Google Scholar]
  13. Deeks S. G., Smith M., Holodniy M., Kahn J. O. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997 Jan 8;277(2):145–153. [PubMed] [Google Scholar]
  14. Deminie C. A., Bechtold C. M., Stock D., Alam M., Djang F., Balch A. H., Chou T. C., Prichard M., Colonno R. J., Lin P. F. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother. 1996 Jun;40(6):1346–1351. doi: 10.1128/aac.40.6.1346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Eron J. J., Jr, Johnson V. A., Merrill D. P., Chou T. C., Hirsch M. S. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrob Agents Chemother. 1992 Jul;36(7):1559–1562. doi: 10.1128/aac.36.7.1559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gao W. Y., Johns D. G., Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides. Mol Pharmacol. 1994 Oct;46(4):767–772. [PubMed] [Google Scholar]
  17. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  18. Johnson V. A., Merrill D. P., Videler J. A., Chou T. C., Byington R. E., Eron J. J., D'Aquila R. T., Hirsch M. S. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis. 1991 Oct;164(4):646–655. doi: 10.1093/infdis/164.4.646. [DOI] [PubMed] [Google Scholar]
  19. Karlsson A., Reichard P., Eckstein F. Hydroxyurea increases the phosphorylation of 3'-fluorothymidine and 3'-azidothymidine in CEM cells. Eur J Biochem. 1989 Dec 22;186(3):689–694. doi: 10.1111/j.1432-1033.1989.tb15261.x. [DOI] [PubMed] [Google Scholar]
  20. Kempf D. J., Marsh K. C., Denissen J. F., McDonald E., Vasavanonda S., Flentge C. A., Green B. E., Fino L., Park C. H., Kong X. P. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2484–2488. doi: 10.1073/pnas.92.7.2484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kempf D. J., Marsh K. C., Kumar G., Rodrigues A. D., Denissen J. F., McDonald E., Kukulka M. J., Hsu A., Granneman G. R., Baroldi P. A. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997 Mar;41(3):654–660. doi: 10.1128/aac.41.3.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Markowitz M., Saag M., Powderly W. G., Hurley A. M., Hsu A., Valdes J. M., Henry D., Sattler F., La Marca A., Leonard J. M. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995 Dec 7;333(23):1534–1539. doi: 10.1056/NEJM199512073332204. [DOI] [PubMed] [Google Scholar]
  23. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P. J., Mo H. M., Markowitz M., Chernyavskiy T., Niu P., Lyons N. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996 Jul;2(7):760–766. doi: 10.1038/nm0796-760. [DOI] [PubMed] [Google Scholar]
  24. Partaledis J. A., Yamaguchi K., Tisdale M., Blair E. E., Falcione C., Maschera B., Myers R. E., Pazhanisamy S., Futer O., Cullinan A. B. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol. 1995 Sep;69(9):5228–5235. doi: 10.1128/jvi.69.9.5228-5235.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Patick A. K., Mo H., Markowitz M., Appelt K., Wu B., Musick L., Kalish V., Kaldor S., Reich S., Ho D. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother. 1996 Feb;40(2):292–297. doi: 10.1128/aac.40.2.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Poppe S. M., Slade D. E., Chong K. T., Hinshaw R. R., Pagano P. J., Markowitz M., Ho D. D., Mo H., Gorman R. R., 3rd, Dueweke T. J. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother. 1997 May;41(5):1058–1063. doi: 10.1128/aac.41.5.1058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Prichard M. N., Prichard L. E., Shipman C., Jr Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother. 1993 Mar;37(3):540–545. doi: 10.1128/aac.37.3.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Roberts N. A. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS. 1995 Dec;9 (Suppl 2):27–S32. [PubMed] [Google Scholar]
  29. Schapiro J. M., Winters M. A., Stewart F., Efron B., Norris J., Kozal M. J., Merigan T. C. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med. 1996 Jun 15;124(12):1039–1050. doi: 10.7326/0003-4819-124-12-199606150-00003. [DOI] [PubMed] [Google Scholar]
  30. Schmit J. C., Ruiz L., Clotet B., Raventos A., Tor J., Leonard J., Desmyter J., De Clercq E., Vandamme A. M. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS. 1996 Aug;10(9):995–999. doi: 10.1097/00002030-199610090-00010. [DOI] [PubMed] [Google Scholar]
  31. St Clair M. H., Millard J., Rooney J., Tisdale M., Parry N., Sadler B. M., Blum M. R., Painter G. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res. 1996 Jan;29(1):53–56. doi: 10.1016/0166-3542(95)00916-7. [DOI] [PubMed] [Google Scholar]
  32. Thaisrivongs S., Skulnick H. I., Turner S. R., Strohbach J. W., Tommasi R. A., Johnson P. D., Aristoff P. A., Judge T. M., Gammill R. B., Morris J. K. Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem. 1996 Oct 25;39(22):4349–4353. doi: 10.1021/jm960541s. [DOI] [PubMed] [Google Scholar]
  33. Tisdale M., Myers R. E., Maschera B., Parry N. R., Oliver N. M., Blair E. D. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother. 1995 Aug;39(8):1704–1710. doi: 10.1128/aac.39.8.1704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Vella S., Galluzzo C., Giannini G., Pirillo M. F., Duncan I., Jacobsen H., Andreoni M., Sarmati L., Ercoli L. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res. 1996 Jan;29(1):91–93. doi: 10.1016/0166-3542(95)00926-4. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES